Rocket Pharmaceuticals' CEO Dr. Gaurav Shah on FDA's Clinical Holds on Gene Therapy Trials

Cell & Gene: The Podcast

English - March 31, 2022 08:00 - 26 minutes - 18.5 MB - ★★★★★ - 35 ratings
Life Sciences Science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Inside Solid Tumor Therapies with BlueSphere Bio’s CEO Dr. David Apelian

Next Episode: Pivoting to Allogeneic CAR-T Therapies with Celyad Oncology’s CMO, Dr. Charlie Morris

We love to hear from our listeners. Send us a message.

Rocket Pharmaceuticals CEO Dr. Gaurav Shah offers his take on why gene therapy developers have been plagued by clinical holds, whether the FDA’s AAV-focused CTGTAC meeting's takeaways will hold up throughout 2022, and more.